Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the complexities and challenges in classifying systemic lupus erythematosus and the problematic role of the anti-dsDNA antibody as a biomarker, without presenting new experimental findings.

This study identified distinct clinical and dermatoscopic features to differentiate non-scarring patchy alopecia in SLE from alopecia areata, emphasizing the value of serological tests in diagnosis.

This study found that systemic corticosteroids led to satisfactory hair regrowth in 38.9% of severe alopecia areata patients, but hair fall occurred upon therapy discontinuation or tapering.

This study found that trichoscopic examination is useful for diagnosing and monitoring systemic lupus erythematosus, with severe diffuse non-scarring alopecia indicating active disease.

This study found that systemic mycophenolate mofetil and topical clobetasol were equally effective at reducing lichen planopilaris activity over six months, but satisfaction differed between the treatments.

This review details the diverse catalytic activities of abzymes in systemic lupus erythematosus (SLE) and reports no new experimental findings; it discusses the impact of these abzymes on disease pathogenesis.

This study found that a 6-week taper of prednisone led to more than 25% hair regrowth in 30% to 47% of alopecia areata patients, and applying 2% topical minoxidil helped maintain this growth.

This article discusses systemic lupus erythematosus (SLE) as a complex chronic inflammatory condition with a variable clinical course, impacting multiple organs, and reports no new research findings.

This study found that a vitamin B-group and L-cystine combination therapy improved hair quality and growth in women with diffuse effluvia, with one formulation showing greater efficacy than another and both performing better than placebo.

This case study suggests that systemic lupus erythematosus should be considered as a potential diagnosis for immune-mediated skin disease in horses, based on multisystemic signs and specific histopathologic and immunopathologic findings.

This study reviewed the initial clinical presentation of SLE patients in Oman, revealing diverse symptoms and highlighting the importance of nationwide collaboration for effective management of the condition.

This study developed a vascularized full-thickness skin equivalent with a complex vascular network, enhancing its predictiveness for topical and systemic drug applications in dermatology research.

This guideline provides evidence-based recommendations for prescribing testosterone therapy to women with hypoactive sexual desire disorder, noting a moderate therapeutic benefit but highlighting limited data and regulatory challenges.

This review discusses the topical use of systemic drugs for cutaneous disorders and reports a lack of strong evidence from randomized controlled trials, highlighting the need for larger comparative effectiveness studies.

This case report demonstrates a strong association between protein-losing enteropathy and systemic lupus erythematosus, with symptoms and conditions improving with prednisolone treatment.

Hair growth phase in mice weakens certain immune responses.

This review indicates that many former FDA category D and X systemic dermatologic medications may negatively impact male fertility, with further research needed to assess potential teratogenic effects.

This study reports that sequential high- and low-dose prednisolone therapy effectively promotes complete hair regrowth in 62% of children with severe alopecia areata, while minimizing severe side effects.

This paper reviews seven major systemic causes of hair loss and provides a clinical evaluation framework but reports no new experimental results.

This case report describes a patient with SLE who developed acute inflammatory demyelinating polyneuropathy, experiencing significant improvement after treatment with intravenous immunoglobulin, methylprednisolone, and cyclophosphamide.

This study found that incorporating 0.5% TPGS into topical minoxidil solutions enhanced hair growth in mice, although increasing TPGS to 2% decreased effectiveness.

In this study, Koreans with rosacea showed higher odds of experiencing various systemic comorbidities, including autoimmune diseases and certain cancers, compared to controls.

In this study, baricitinib improved the resolution of arthritis or rash in patients with systemic lupus erythematosus, but outcomes for skin involvement like alopecia were not reported.

This study described a case where lupus erythematosus panniculitis preceded the diagnosis of systemic lupus erythematosus, highlighting the need for regular follow-ups in LEP patients for potential SLE development.

This article reviews side effects and relapse rates of various systemic treatments for severe alopecia areata, reporting no new clinical findings.

This study reported that high-dose mizoribin therapy may be effective and safe for managing steroid-dependent pediatric systemic lupus erythematosus but requires monitoring of serum uric acid levels due to potential side effects.

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

This study observed that in children who unintentionally consumed high-dose oral minoxidil, 65% developed hypertrichosis, predominantly on the face, and 15% experienced mild systemic side effects.

This study reports that systemic lupus erythematosus patients with Evans syndrome often exhibited photosensitivity, hypocomplementemia, and elevated serum IgG, while lupus nephritis was less common, suggesting distinct clinical features.

In this study, severe diffuse hair loss in patients with systemic lupus erythematosus was associated with distinct clinical, dermoscopic, and histopathological features, which improved alongside treatment of the underlying condition.